Search research articles
Contact Us
Filters
Showing results (61-70 of 109) with videos related to
Page
of 11
Sort By:
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|
January 31, 2008
Globus pallidus stimulation reduces frontal hyperactivity in tardive dystonia
Stéphane Thobois, Bénédicte Ballanger, Jing Xie-Brustolin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
August 24, 2017
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)
Wolfgang Oertel, Karla Eggert, Rajesh Pahwa, et al.
Muscle & Nerve
|
September 17, 2024
Electrophysiological features of the peripheral neuropathy in patients with pathologic biallelic RFC1 repeat expansions
Claudia Calezis, Nathalie Bonello-Palot, Annie Verschueren, et al.
Annales De Biologie Clinique
|
February 11, 2021
[SARS-CoV-2 and neurological disorders: the revelance of biomarkers?]
Edith Bigot-Corbel, Aymeric Lanore, Celia Raulet, et al.
Parkinsonism & Related Disorders
|
May 22, 2024
Energetic dysfunction and iron overload in early Parkinson's disease: Two distinct mechanisms?
Stephan Grimaldi, Arnaud Le Troter, Mohamed Mounir El Mendili, et al.
Parkinsonism & Related Disorders
|
September 27, 2025
Comparison of tetrabenazine, tiapride and olanzapine in Huntington's disease: a one-year French randomized multicenter study (Neuro-HD)
Katia Youssov, Etienne Audureau, Jérémie Pariente, et al.
Journal of Psychosomatic Research
|
November 26, 2025
Functional movement and gait disorders: A matter of age?
Gilbert Kanyinda Kayombo, Tatiana Witjas, Camille Comet, et al.
Parkinsonism & Related Disorders
|
May 2, 2021
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients
Stuart H Isaacson, Clive G Ballard, David L Kreitzman, et al.
Plos One
|
September 15, 2016
Insulin-Like Growth Factor-1 but Not Insulin Predicts Cognitive Decline in Huntington's Disease
Linda Salem, Nadine Saleh, Gaelle Désaméricq, et al.
Parkinsonism & Related Disorders
|
July 27, 2020
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis
Clive G Ballard, David L Kreitzman, Stuart Isaacson, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 109) with videos related to
Sort By:
Page
of 11
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|
January 31, 2008
Globus pallidus stimulation reduces frontal hyperactivity in tardive dystonia
Stéphane Thobois, Bénédicte Ballanger, Jing Xie-Brustolin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
August 24, 2017
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)
Wolfgang Oertel, Karla Eggert, Rajesh Pahwa, et al.
Muscle & Nerve
|
September 17, 2024
Electrophysiological features of the peripheral neuropathy in patients with pathologic biallelic RFC1 repeat expansions
Claudia Calezis, Nathalie Bonello-Palot, Annie Verschueren, et al.
Annales De Biologie Clinique
|
February 11, 2021
[SARS-CoV-2 and neurological disorders: the revelance of biomarkers?]
Edith Bigot-Corbel, Aymeric Lanore, Celia Raulet, et al.
Parkinsonism & Related Disorders
|
May 22, 2024
Energetic dysfunction and iron overload in early Parkinson's disease: Two distinct mechanisms?
Stephan Grimaldi, Arnaud Le Troter, Mohamed Mounir El Mendili, et al.
Parkinsonism & Related Disorders
|
September 27, 2025
Comparison of tetrabenazine, tiapride and olanzapine in Huntington's disease: a one-year French randomized multicenter study (Neuro-HD)
Katia Youssov, Etienne Audureau, Jérémie Pariente, et al.
Journal of Psychosomatic Research
|
November 26, 2025
Functional movement and gait disorders: A matter of age?
Gilbert Kanyinda Kayombo, Tatiana Witjas, Camille Comet, et al.
Parkinsonism & Related Disorders
|
May 2, 2021
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients
Stuart H Isaacson, Clive G Ballard, David L Kreitzman, et al.
Plos One
|
September 15, 2016
Insulin-Like Growth Factor-1 but Not Insulin Predicts Cognitive Decline in Huntington's Disease
Linda Salem, Nadine Saleh, Gaelle Désaméricq, et al.
Parkinsonism & Related Disorders
|
July 27, 2020
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis
Clive G Ballard, David L Kreitzman, Stuart Isaacson, et al.
Page
of 11